Intermittent fasting and changes in clinical risk scores: Secondary analysis of a randomized controlled trial

作者：Benjamin Davies Horne, Jeffrey L. Anderson, Heidi Thomas May, Viet Trung Le, Tami L. Bair, Sterling T. Bennett, Kirk U. Knowlton, Joseph Brent Muhlestein · 发表于：International Journal of Cardiology Cardiovascular Risk and Prevention · 年份：2023 · DOI：10.1016/j.ijcrp.2023.200209 · 被引用次数：6 · 研究领域：Dietary Effects on Health、Genetics, Aging, and Longevity in Model Organisms、Diet and metabolism studies

Intermittent fasting may increase longevity and lower cardiometabolic risk. This study evaluated whether fasting modifies clinical risk scores for mortality [i.e., Intermountain Mortality Risk Score (IMRS)] or chronic diseases [e.g., Pooled Cohort Risk Equations (PCRE), Intermountain Chronic Disease score (ICHRON)]. Subjects (N = 71) completing the WONDERFUL trial were aged 21–70 years, had ≥1 metabolic syndrome criteria, elevated cholesterol, and no anti-diabetes medications, statins, or chronic diseases. The intermittent fasting arm underwent 24-h water-only fasting twice-per-week for 4 weeks and once-per-week for 22 weeks (26 weeks total). Analyses examined the IMRS change score at 26 weeks vs. baseline between intermittent fasting (n = 38) and ad libitum controls (n = 33), and change scores for PCRE, ICHRON, HOMA-IR, and a metabolic syndrome score (MSS). Age averaged 49 years; 65% were female. Intermittent fasting increased IMRS (0.78 ± 2.14 vs. controls: −0.61 ± 2.56; p = 0.010) but interacted with baseline IMRS (p-interaction = 0.010) to reduce HOMA-IR (but not MSS) more in subjects with higher baseline IMRS (median HOMA-IR change: fasters, −0.95; controls, +0.05) vs. lower baseline IMRS (−0.29 vs. −0.32, respectively). Intermittent fasting reduced ICHRON (−0.92 ± 2.96 vs. 0.58 ± 3.07; p = 0.035) and tended to reduce PCRE (−0.20 ± 0.22 vs. −0.14 ± 0.21; p = 0.054). Intermittent fasting increased 1-year IMRS mortality risk, but decreased 10-year chronic disease risk (PCR...